Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

AstraZeneca’s investigational therapy gefurulimab has delivered positive results in the pivotal Phase III PREVAIL trial for ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...